Menopausal Disorder Treatment Market Report 2026

The menopausal disorder treatment market size has grown strongly in recent years. It will grow from $11.47 billion in 2025 to $12.32 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growing aging female population, widespread use of hormone replacement therapy, increased diagnosis of menopausal symptoms, expansion of gynecology care services, rising healthcare access for women.

The menopausal disorder treatment market size is expected to see strong growth in the next few years. It will grow to $16.26 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in demand for safer menopause treatments, increasing focus on individualized therapy plans, rising awareness of long-term hrt risks, expansion of digital women’s health platforms, growing adoption of preventive women’s healthcare. Major trends in the forecast period include rising preference for non-hormonal menopause therapies, increasing adoption of personalized hormone replacement therapy, growing use of lifestyle and behavioral interventions, expansion of herbal and natural menopause treatments, increasing awareness of menopause symptom managemen.

The growing demand for hormone replacement therapies (HRT) is expected to drive the growth of the menopausal disorder treatment market in the coming years. Hormone replacement therapy involves supplementing or replacing hormones to relieve symptoms associated with menopause or hormonal imbalances. This demand is fueled by increased awareness and the need for effective management of menopausal symptoms. HRT addresses menopausal disorders by replenishing estrogen and progesterone levels, restoring hormonal balance, and alleviating disruptive symptoms such as hot flashes, night sweats, and mood swings, thereby improving quality of life. For example, in October 2024, the NHS Business Services Authority (NHSBSA), a UK-based support services organization, reported that HRT prescriptions increased by 22% to 13 million, while the number of identified patients rose by 12%, from 2.3 million in 2022/23 to 2.6 million in 2023/24. Consequently, the rising demand for hormone replacement therapies is fueling the growth of the menopausal disorder treatment market.

Major companies in the menopausal disorder treatment market are developing innovative nonhormonal neurokinin 3 (NK3) receptor antagonist therapies to manage vasomotor symptoms effectively without using hormone therapy. These novel therapies work by blocking NK3 receptors to alleviate menopausal symptoms without hormones. For example, in December 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received European Commission approval for Veozah (fezolinetant), a nonhormonal NK3 receptor antagonist for treating moderate to severe vasomotor symptoms (VMS), including hot flashes and night sweats in menopausal women. Veozah targets neurons in the brain’s temperature regulation center to reduce the frequency and intensity of these symptoms.

In February 2025, Cosette Pharmaceuticals, a US-based specialty pharmaceutical company focused on women’s health and dermatology, acquired Mayne Pharma Pty Ltd. (Australia) for US$430 million. The acquisition strengthens Cosette Pharmaceuticals’ position in the women’s health market by adding patented, high-growth menopause therapies and expanding its portfolio of dermatology and specialty products. Mayne Pharma Pty Ltd. is an Australia-based company that provides women’s health products, including menopause medications such as Bijuva, Intrarosa, and Imvexxy, along with other specialty and dermatology drugs.

Major companies operating in the menopausal disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co Inc., Novartis AG, Bayer AG, Bristol-Myers Squibb Company, Sanofi SA, AstraZeneca plc, Eli Lilly and Company, Novo Nordisk A/S, Abbott Laboratories, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Ipsen SA, Dr. Reddy’s Laboratories Ltd., Theramex, Besins Healthcare, Mithra Pharmaceuticals, Duchesnay USA, Fervent Pharmaceuticals, Joylux Inc., TherapeuticsMD Inc.

North America was the largest region in the menopausal disorder treatment market in 2025. The regions covered in the menopausal disorder treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the menopausal disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the menopausal disorder treatment market by increasing costs of imported hormone formulations, active pharmaceutical ingredients, and specialty supplements. These effects are most evident in hormone replacement therapy and non-hormonal drug segments, particularly across North America, Europe, and Asia-Pacific. Higher tariffs have contributed to increased treatment costs in hospital and retail pharmacy channels. However, tariffs have also encouraged local drug manufacturing and wider adoption of lifestyle-based and non-pharmacological menopause management options.

The menopausal disorder treatment market research report is one of a series of new reports that provides menopausal disorder treatment market statistics, including menopausal disorder treatment industry global market size, regional shares, competitors with a menopausal disorder treatment market share, detailed menopausal disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the menopausal disorder treatment industry. This menopausal disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Menopausal disorder treatment refers to medical and therapeutic interventions designed to relieve symptoms associated with menopause, such as hot flashes, mood changes, sleep disturbances, and hormonal imbalances, with the goal of improving the quality of life and well-being of individuals during the menopausal transition.

The primary treatment types for menopausal disorders include hormone replacement therapy, non-hormonal treatments, herbal supplements, and lifestyle modifications. Hormone replacement therapy (HRT) helps restore hormone balance in women experiencing menopause-related symptoms such as hot flashes, mood swings, and bone density loss. These treatments are applicable across different stages, including menopause, postmenopause, and perimenopause, and address symptoms such as hot flashes, night sweats, mood swings, and vaginal dryness. They are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are used by hospitals, specialty clinics, homecare settings, and other end users.

The menopausal disorder treatment market includes revenues earned by entities providing services such as estrogen-only therapy, combined estrogen and progesterone therapy, bone health management, and hormone level testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The menopausal disorder treatment market also includes sales of hormone replacement therapy (HRT) medications, non-hormonal therapies, dietary supplements, and vaginal estrogen products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.